X
Fourth Humira biosimilar set for EU approval
https://pharmaphorum.com/news/humira-biosimilar-eu-sandoz-chmp/
biosimilars Europe
EC to update IP rules to benefit generic exports
The European Commission (EC) is proposing to adjust intellectual property (IP) rules to help Europe’s pharma companies tap into fast-growing global markets.
3 Questions on biosimilars in Europe: Adrian van den Hoven
Adrian van den Hoven of Medicines for Europe addresses three big questions facing the biosmilars sector in Europe in 2018.
